ACQUITY™ UPLC™ I-Class SM-FL/Xevo™ TQ Absolute System: Analytical Performance for Free Testosterone

Importance of the Topic

Accurate measurement of free testosterone in serum is critical for the diagnosis and monitoring of androgen disorders, fertility assessments, and endocrine research. Highly sensitive and precise analytical techniques are required to quantify low concentrations of unbound hormone in complex biological matrices, supporting clinical decision-making and therapeutic monitoring.

Objectives and Study Overview

This application note evaluates the analytical capabilities of the Waters ACQUITY UPLC I-Class SM-FL/Xevo TQ Absolute IVD system for quantifying free testosterone in human serum. Key aims include assessing the linearity, sensitivity, precision, and overall suitability of this combined ultra-performance liquid chromatography (UPLC) and tandem mass spectrometry (MS/MS) platform under routine laboratory conditions.

Methodology

Serum samples (200 µL) underwent equilibrium dialysis to isolate the free fraction of testosterone. The dialysate was extracted using methyl tert-butyl ether in a liquid–liquid procedure to yield a clean analyte extract. Chromatographic separation was achieved on an ACQUITY UPLC BEH C18 column (1.7 µm, 2.1 × 100 mm) using a binary gradient of 0.2 mM ammonium fluoride in water and methanol at 0.30 mL/min. The gradient started at 50% organic, ramped to 98% over 3.25 minutes, and returned to initial conditions for re-equilibration.

Instrumentation

• UPLC System: Waters ACQUITY UPLC I-Class SM-FL sample manager (PL, load ahead disabled)
• Solvent Manager: Binary solvent manager (BSM)
• Column: ACQUITY UPLC BEH C18, 1.7 µm, 2.1 × 100 mm
• Mass Spectrometer: Xevo TQ Absolute triple quadrupole with ESI in positive mode
• Software: MassLynx v4.2 for control; TargetLynx XS for data processing

Key Results and Discussion

The method exhibited highly linear calibration over the clinically relevant concentration range, with correlation coefficients (r2) exceeding 0.995. The lower limit of quantification (LLOQ) met criteria of signal-to-noise >10 and precision (%RSD) ≤20%, with reproducibility assessed over five days (n=50). Quality control samples demonstrated total precision and repeatability (%RSD) below 10% (n=25). External quality assessment (EQA) bias, determined against an all-laboratory trimmed mean (n=45), remained within ±15%, confirming method accuracy. A representative chromatogram illustrates clear peak resolution and low baseline noise.

Benefits and Practical Applications

• High sensitivity and low LLOQ enable reliable detection of low free testosterone levels in clinical samples
• Robust precision and accuracy support routine use in diagnostic laboratories
• Automated sample handling and software streamline workflow and data processing
• Versatile platform adaptable to other steroid hormones and small molecules

Future Trends and Opportunities

Advances in miniaturized dialysis devices and high-throughput robotic extraction could further enhance sample preparation efficiency. Integration with laboratory information management systems (LIMS) and expansion to multiplexed assays may broaden clinical and research applications. Emerging ionization techniques and next-generation mass analyzers promise even greater sensitivity and faster throughput for hormone panels.

Conclusion

The Waters ACQUITY UPLC I-Class SM-FL/Xevo TQ Absolute IVD system demonstrates excellent performance for measuring free testosterone in serum, combining high sensitivity, precision, and accuracy. Its robust workflow and data integrity make it a promising solution for clinical laboratories and research settings focused on endocrine analysis.

References

• No external references were provided in the original text.